Overexpression of phosphorylated STAT-1α in the labial salivary glands of patients with sjögren's syndrome

Arthritis and Rheumatism

Volumn 54, Issue 11, 2006, Pages 3476-3484

  Wakamatsu, Ei ^a   Matsumoto, Isao ^a   Yasukochi, Takanori ^a   Naito, Yusuke ^a   Goto, Daisuke ^a   Mamura, Mizuko ^a   Ito, Satoshi ^a   Tsutsumi, Akito ^a   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON REGULATORY FACTOR 1; MESSENGER RNA; SERINE; STAT1 ALPHA PROTEIN; STAT1 BETA PROTEIN; STAT1 PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DUCTAL EPITHELIUM; GENE; GENE FUNCTION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABIAL SALIVARY GLAND; LYMPHOCYTIC INFILTRATION; MOLECULAR DYNAMICS; MOUTH MUCOSA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND; SALIVARY GLAND DUCT; SJOEGREN SYNDROME; STAT 1 GENE; UPREGULATION; WESTERN BLOTTING;

GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON-STIMULATED GENE FACTOR 3; PHOSPHORYLATION; RNA, MESSENGER; SALIVARY DUCTS; SALIVARY GLANDS, MINOR; SERINE; SJOGREN'S SYNDROME; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; TYROSINE;

EID: 33750964018     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22176     Document Type: Article

References (50)

1. Arnett FC, Hamilton RG, Reveille JD, Bias WB, Harley JB, Reichlin M. Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum 1989;32:413-9.
2. Naito Y, Matsumoto I, Wakamatsu E, Goto D, Sugiyama T, Matsumura R, et al. Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome. Ann Rheum Dis 2005;64:510-1.
3. Sumida T, Matsumoto I, Maeda T, Nishioka K. T-cell receptor in Sjögren's syndrome. Br J Rheumatol 1997;36:622-9.
4. Fox IR, Kang IH, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994;152:5532-9.
5. Ohyama Y, Nakamura S, Matsuzaki G, Shinohara M, Hiroki A, Fujimura T, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996;39:1376-84.
6. Mitsias ID, Tzioufas GA, Veiopoulou C, Zintzaras E, Tassios KI, Kougopoulou O, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol 2002;128:562-8.
7. Moutsopoulos HM, Hooks JJ, Chan CC, Dalavanga YA, Skopouli FN, Detrick B. HLA-DR expression by labial salivary gland tissues in Sjögren's syndrome. Ann Rheum Dis 1986;45:677-83.
8. Kong L, Ogawa N, Nakabayashi T, Liu GT, D'Souza E, McGuff HS, et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997;40:87-97.
9. Sumida T, Matsumoto I, Namekawa T, Matsumura R, Tomioka H, Iwamoto I, et al. TCR in Fas-sensitive T cells from labial salivary glands of patients with Sjögren's syndrome. J Immunol 1997;15:1020-5.
10. Bolstad IA, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum 2003;48:174-85.
11. Azuma T, Takei M, Yoshikawa T, Nagasugi Y, Kato M, Otsuka M, et al. Identification of candidate genes for Sjögren's syndrome and cDNA microarray analysis. Immunol Lett 2002;81:171-6.
12. Kawasaki S, Kawamoto S, Yokoi N, Connon C, Minesaki Y, Kinoshita S, et al. Up-regulated gene expression in the conjunctival epithelium of patients with Sjögren's syndrome. Exp Eye Res 2003;77:7-26.
13. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44.
14. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity. Mod Rheumatol 2004;14:425-34.
15. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974;37:217-29.
16. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996;84:331-4.
17. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001;108:1781-8.
18. Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004;63:233-9.
19. De Hooge AS, van de Loo FA, Koenders MI, Bennink MB, Arntz OJ, Kolbe T, et al. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum 2004;50:2014-23.
20. Wang F, Sengupta TK, Zhong Z, Ivashkiv LB. Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med 1995;182:1825-31.
21. Suk K, Kim S, Kim YH, Kim KA, Chang I, Yagita H, et al. IFN-γ/TNF-α synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic β cell death. J Immunol 2001;166:4481-9.
22. Flodstrom-Tullberg M, Yadav D, Hagerkvist R, Tsai D, Secrest P, Stotland A, et al. Target cell expression of suppressor of cytokine signaling-1 prevents diabetes in the NOD mouse. Diabetes 2003;52:2696-700.
23. Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, Tian Z, et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 2002;110:1503-13.
24. Siebler J, Wirtz S, Klein S, Protschka M, Blessing M, Galle PR, et al. A key pathogenic role for the STAT1/T-bet signaling pathway in T-cell-mediated liver inflammation. Hepatology 2003;38:1573-80.
25. Cha S, Brayer J, Gao J, Brown V, Killedar S, Yasunari U, et al. A dual role for interferon-γ in the pathogenesis of Sjögren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol 2004;60:552-65.
26. Wu AJ, Chen ZJ, Kan EC, Baum BJ. Interferon-γ-induced JAK2 and STAT1 signalling in a human salivary gland cell line. J Cell Physiol 1997;173:110-4.
27. Greenlund AC, Farrar MA, Viviano BL, Schreiber RD. Ligand-induced IFNγ receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J 1994;13:1591-600.
28. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50.
29. Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science 1993;261:1744-6.
30. Stephanou A, Scarabelli TM, Brar BK, Nakanishi Y, Matsumura M, Knight RA, et al. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J Biol Chem 2001;276:28340-7.
31. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997;61:246-57.
32. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996;184:963-9.
33. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998;28:3696-705.
34. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-7-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002;168:3195-204.
35. Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001;98:39-45.
36. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-15.
37. Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-γ-induced T cell-attracting chemokines, interferon-γ- inducible 10-kd protein (CXCL10) and monokine induced by interferon-γ (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis Rheum 2002;46:2730-41.
38. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84:431-42.
39. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-50.
40. Ruffner H, Reis LF, Naf D, Weissmann C. Induction of type I interferon genes and interferon-inducible genes in embryonal stem cells devoid of interferon regulatory factor 1. Proc Natl Acad Sci USA 1993;90:11503-7.
41. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994;77:829-39.
42. Tanaka N, Ishihara M, Lamphier MS, Nozawa H, Matsuyama T, Mak TW, et al. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 1996;382:816-8.
43. Kano A, Haruyama T, Akaike T, Watanabe Y. IRF-1 is an essential mediator in IFN-γ-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun 1999;257:672-7.
44. Xu X, Fu XY, Plate J, Chong AS. IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998;58:2832-7.
45. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
46. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signaling. Nature 1997;387:917-21.
47. Ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002;22:5662-8.
48. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 1998;95:10626-31.
49. Chong MM, Chen Y, Darwiche R, Dudek NL, Irawaty W, Santamaria P, et al. Suppressor of cytokine signaling-1 overexpression protects pancreatic β cells from CD8+ T cell-mediated autoimmune destruction. J Immunol 2004;172:5714-21.
50. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE Jr, Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998;93:827-39.